However, even with these promising developments, the largely unregulated exploitative marketplace for selling GLP-1 products persists and now involves marketing personalized compounded GLP-1 weight-loss drugs, which can cause harm due to unknown formulations, dosing errors, and severe side effects
But numbers without records are numbers you will eventually forget, misremember, or confuse
Synergistic with GLP-1 agonists - the CagriSema combination (cagrilintide + semaglutide) shows 15.6% weight loss
Reduced potency on top of metabolic adaptation creates a double barrier to continued progress
While tirzepatide is FDA-approved individually (as Mounjaro and Zepbound) and levocarnitine is FDA-approved for carnitine deficiency (as Carnitor), the specific combination has not been evaluated by the FDA for safety or efficacy
(Most of the budget goes to the military and to entitlements such as Social Security and Medicarethe federal government is sometimes described as an insurance company with an army.) Still, funding for science dwarfs funding for many other worthy pursuitsthe NIH budget is more than 100 times the $200 million allotted annually for the National Endowment for the Arts, for example